Market Overview

Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst

Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst
Related KMPH
60 Biggest Movers From Yesterday
66 Stocks Moving In Wednesday's Mid-Day Session

KemPharm Inc (NASDAQ: KMPH) has struggled to gain traction since its 2015 initial public offering, but one long-sidelined analyst is ready for action.

The Rating

Janney analyst Ken Trbovich initiated coverage of KemPharm with a Buy and $17 price target.

The Thesis

Janney anticipates a “transformative catalyst” in the late June or early July release of Phase 3 data on a new ADHD therapy.

“For years, I tracked KemPharm as it struggled to eventually gain FDA approval of its first prodrug for pain, but we expect value creating events are coming soon from its efforts to develop a prodrug version of d-methylphenidate for treating ADHD,” Trbovich said in a Wednesday note. 

Considering the prodrug’s previously demonstrated efficacy, the analyst calculated high odds of positive Phase 3 outcomes.

If approved, the treatment could become the first ADHD stimulant bearing an abuse-deterrent label given its positive and upcoming results in comparative studies for “drug liking." 

For Trbovich, the only point of caution for KemPharm is its balance sheet.

“While we see this as being of little concern if the data is positive, it could be extremely challenging if it is not." 

Price Action

KemPharm shares were up 8.2 percent at the time of publication midday Wednesday. 

Related Links:

KemPharm Spikes On FDA Approval Of Apadaz

Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Latest Ratings for KMPH

May 2018Janney CapitalInitiates Coverage OnBuy
Feb 2018Canaccord GenuityMaintainsBuyBuy
Dec 2016Canaccord GenuityAssumesBuy

View More Analyst Ratings for KMPH
View the Latest Analyst Ratings

Posted-In: Janney. Ken TrbovichAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (KMPH)

View Comments and Join the Discussion!

Latest Ratings

MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Eurozone Flash PMIs See Further Deterioration In The Economic Activity

EUR/USD Forecast: 3 Reasons Pushing The Pair To A 6-month Low